Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: paintransplantrequiringventricularmelanoma
  Phrases that lowered it: safetypharmacokineticoralopen label65
• Sponsor's past termination rate: 50% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 24.6% (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Keywords listed: 6 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports marked serious: 93.0% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies NCT03465540 · started 2018 · scored riskier than 66% of active trials terminated
• Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma NCT03836053 · started 2019 · scored riskier than 59% of active trials terminated
• A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma NCT02998047 · started 2016 · scored riskier than 42% of active trials terminated
• Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies NCT01658319 · started 2011 · scored riskier than 93% of active trials completed
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma NCT01421524 · started 2011 · scored riskier than 89% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.